Catheter Precision (VTAK) Expected to Announce Earnings on Monday

Catheter Precision (NYSEAMERICAN:VTAK) is anticipated to issue its results before the market opens on Monday, August 17th. Analysts expect Catheter Precision to post earnings of ($19.00) per share and revenue of $2.00 million for the quarter.

Catheter Precision (NYSEAMERICAN:VTAK) last announced its quarterly earnings results on Monday, May 18th. The company reported ($1.39) EPS for the quarter, beating analysts’ consensus estimates of ($20.90) by $19.51. The firm had revenue of $0.43 million during the quarter, compared to the consensus estimate of $1.60 million. Catheter Precision had a negative net margin of 1,297.56% and a negative return on equity of 76.51%.

Catheter Precision Stock Performance

VTAK opened at $0.28 on Monday. The stock has a 50-day moving average of $0.74 and a 200 day moving average of $1.10. The company has a current ratio of 0.06, a quick ratio of 0.06 and a debt-to-equity ratio of 0.35. Catheter Precision has a 12 month low of $0.23 and a 12 month high of $4.31. The firm has a market cap of $1.01 million, a P/E ratio of -0.02 and a beta of -1.00.

Hedge Funds Weigh In On Catheter Precision

A hedge fund recently bought a new position in Catheter Precision stock. Millennium Management LLC purchased a new position in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned about 2.08% of Catheter Precision as of its most recent SEC filing. 20.34% of the stock is currently owned by institutional investors and hedge funds.

Catheter Precision Company Profile

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.